



20th KM Hosur Road, Electronics City, Bangalore 560 100

Bangalore, January 17, 2017

Biocon's Q3 FY 2017-18 Results Conference Call

At 9.00 am IST on January 25, 2018

Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will announce results for the third quarter of fiscal 2017-18, ended December 31, 2017 on January 24, 2018. Following the announcement, the management of Biocon Limited will host an earnings call to discuss the Company's performance on January 25, 2018.

Details of the conference call are as under:

Date:	Thursday, January 25, 2018
Time:	9.00 am IST
Dial-in Numbers:	
When using dial-in numbers mentioned below please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time. Please inform the operator that you would like to join " Biocon Ltd. Q3FY18 Earnings Conference Call ".	
Primary Number	+91 22 3938 1081
Local Access (all over India)	+91 70456 71221
International Local Access Numbers	USA: +1 323 386 8721 UK: +44 20 3478 5524 Singapore: +65 3157 5746 Hong Kong: +852 3018 6877
Replay Facility	The replay will be available after the earnings call ends. Replay available till February 1, 2018 (23:50 IST) Dial in number: +91 22 3065 2322 Playback Code: 17384
Transcript	Will be made available after a few days on the Company's website: www.biocon.com

Please note: This call is not open to the members of the media (print/online)

About Biocon

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 120 countries, it is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and commercialized a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs.

Some of its key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAb® (Trastuzumab), BIOMAb EGFR® (Nimotuzumab), KRABEVA® (Bevacizumab), Evertor® (Everolimus) and ALZUMAb™ (Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. The Company has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin. For more: www.biocon.com; Follow us on twitter: [@bioconlimited](https://twitter.com/bioconlimited)

Contact:

For further information please contact:

Saurabh Paliwal

Investor Relations – Biocon Limited

☎ +91 80 6775 2040

✉: investor.relations@biocon.com

Diwakar Pingle

Christensen Investor Relations

☎ +91 22 4215 0210

✉: dpingle@ChristensenIR.com

Safe Harbor: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current assumptions and expectations concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. There can be no assurance that future developments affecting Biocon and its subsidiaries/associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties that may cause actual results to differ, possibly materially, from those contemplated by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our subsidiaries/ associates have any obligation to update or otherwise revise any statements reflecting circumstances arising after conclusion of the conference call to reflect the occurrence of underlying events, even if the underlying assumptions and expectations do not come to fruition.*